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Abstract 
In an increasing number of states and countries, cannabis now stands poised to join alcohol and 
tobacco as a legal drug. Quantifying the relative adverse and beneficial effects of cannabis and 
its constituent cannabinoids should therefore be prioritised. Whereas newspaper headlines have 
focused on links between cannabis and psychosis, less attention has been paid to the much 
more common problem of cannabis addiction. Certain cognitive changes have also been 
attributed to cannabis use, although their causality and longevity are fiercely debated. 
Identifying why some individuals are more vulnerable than others to the adverse effects of 
cannabis is now of paramount importance to public health. Here we review the current state of 
knowledge about such vulnerability factors, the variations in types of cannabis, and their 
relationship to cognition and addiction.  
 
1. Introduction 
For millennia, cannabis has been used medically and for religious purposes, most notably in 
China and India. The plant and its many constituent cannabinoids are now becoming 
increasingly important in modern medicine, particularly in the treatment of chronic pain and 
spasticity1. A much more widespread global use is for pleasure2: the ‘stoned’ experience varies 
widely across individuals but often includes euphoria, a heightened awareness of music and 
colour, and the tendencies to eat a lot and to giggle profusely2. Despite its pleasurable effects, 
most scientific research has focused on adverse consequences of using the drug, such as 
addiction, cognitive impairment and possible increased risk of psychotic illness3, 4.  
We do not know how patterns of use will change as legalisation proliferates, but even a small 
percentage increase in the current 182 million users worldwide5 will mean a considerable surge 
in absolute numbers. Are we now able to use existing evidence about the less desirable effects 
of cannabis use to help us to look forward to the future? 
This article aims to survey our current state of knowledge about the effects of cannabis and 
then pinpoint how we should be increasing our understanding of the effects of cannabis, given 
its potentially soaring future use. We first summarise the variety of unique ingredients in 
cannabis and outline how its use affects cognition, learning and memory. We survey evidence 
of how the effects of the drug vary according to the maturational state of the brain and then go 
on to discuss cannabis addiction and the mental health problems that are often related to it. 
Finally, we identify the important gaps in our current knowledge and look to the future in terms 
of both research and the current tide of changes to the legislation of cannabis. 
  
2. Cannabis: a plant with many forms 
Purple Haze, Northern Lights, charas, skunk, resin, grass, marijuana, weed… The multitude of 
names for cannabis in part reflects variations in genetics, growing conditions, processing, and 
constituent cannabinoids and terpenoids in different strains of the plant. Of the roughly 100 
unique ingredients in cannabis that are called cannabinoids, most research to date has focused 
on the two most prominent of these: delta-9-tetrahydrocannabinol (Δ9-THC) and cannabidiol 
(CBD). These two compounds appear to have a range of opposing effects on the human brain 
and behaviour. For example, Δ9-THC acutely impairs learning, produces psychosis-like effects 
and increases anxiety6, whereas CBD can enhance learning7 and has antipsychotic8 and anti-
anxiety9 properties in humans. When taken together, CBD may ameliorate the harmful effects 
of Δ9-THC10, 11.  
Δ9-THC acts as a partial agonist at cannabinoid CB1 receptors (CB1Rs), whereas CBD has a 
complex range of pharmacological actions.  For example, although CBD has low affinity for 
CB1R it can attenuate CB1 agonist effects in brain even at low concentrations (e.g. providing 
functional antagonism of CB1R signaling)
12.  Conversely, CBD reduces the cellular reuptake 
and hydrolysis of the endogenous cannabinoid anandamide (AEA) in brain12, 13 Neuroimaging 
studies have documented opposing effects of Δ9-THC and CBD on blood oxygenation level-
dependent (BOLD) signal during performance of several cognitive and emotional tasks, 
including striatal response during memory retrieval and amygdala response to fearful faces14. 
 
Over the past two decades, the Δ9-THC content of street cannabis has risen dramatically, 
whereas its CBD content has decreased to negligible levels. For example, in the United States, 
the Δ9-THC content of street cannabis rose from 4% in 1995 to 12% in 201415. In Europe16 17 
and Australia18, high-potency cannabis containing ~15% Δ9-THC and less than 0.1% CBD now 
dominates the market. Thus, the type of cannabis available years ago differs considerably from 
that sold today, limiting the relevance of older longitudinal cohort studies (for example, the 
New Zealand Birth Cohort study, see Box 1) to the mental health and cognitive function of 
contemporary users. In the United States, the cannabis that the National Institute of Drug Abuse 
supplies to researchers for experiments generally has less than 4% Δ9-THC, and so findings 
from these experiments have limited implications for modern-day cannabis users.  
3. Cognition, learning and memory 
Endocannabinoids (eCBs) are, in a sense, the brain’s own natural cannabis system, and Δ9-
THC and other CB1R agonists alter brain levels of eCBs19, 20. eCBs are neuroactive lipids 
that participate in a range of physiological processes including reward, motivation, emotional 
homeostasis, pain processing, and synaptic plasticity contributing to learning and memory. At 
present, the best-characterized eCBs are N-arachidonylethanolamide (anandamide; AEA) and 
2-arachidonoylglycerol (2-AG)21, 22 and both of these lipids exert agonist activity at CB1Rs 
and CB2Rs. Owing to their lipid nature, AEA and 2-AG are not stored in vesicles but are 
synthesized on an ‘on-demand’ basis, and as such brain eCB levels are critically reliant on the 
balance between evoked biosynthesis and subsequent clearance by intracellular enzyme-
mediated hydrolysis. eCBs are crucial in certain forms of neuronal plasticity, and Δ9-THC has 
been shown to disrupt long-term potentiation (a model for learning and memory) and long-
term depression in preclinical studies23. In this section, we consider the acute and longer-term 
effects of cannabis on cognition, learning and memory, as well as effects potentially 
persisting after an individual has stopped using the drug. We also review evidence on the 
impact of starting cannabis use early in adolescence.  
 
Acute effects. Acute effects are transient and seen in the time period during which the 
individual is intoxicated with the drug (e.g. feeling ‘stoned’ for around 5-120 minutes when 
smoked). A single dose of cannabis or its main active ingredient Δ9-THC robustly and dose-
dependently impairs working and episodic memory24, 25. Memory impairments occur however 
the drug is administered, but the onset of effect is more rapid when it is inhaled or given 
intravenously than when it is ingested orally. Specifically, the encoding of new memories is 
impaired during cannabis intoxication and this leads to subsequent deficits in recalling these 
memories; by contrast, the retrieval of old memories that were consolidated when not under 
the influence is unaffected. Cannabis-induced working-memory deficits are seen more in the 
ability to manipulate information while it is ‘online’ (for example, when doing mental 
arithmetic) than in the ability to simply retain it for brief periods (for example, when 
remembering a telephone number before dialling it). Whereas on placebo, brain activity in the 
dorsolateral prefrontal cortex (DLPFC) increases linearly with a task’s working memory load, 
acute dosing with Δ9-THC prevents this load-associated increase in DLPFC activity26.  
These effects on memory are consistent with the extensive preclinical evidence of: the amnestic 
effects of cannabis in animal models; the high density of cannabinoid receptors in memory-
associated brain regions such as the hippocampus, amygdala and prefrontal cortex (Figure 1); 
and observations that Δ9-THC induces disruption of plasticity (including long-term 
potentiation (LTP) and long-term depression (LTD)) in the hippocampus and decreases 
acetylcholine release here and in the prefrontal cortex (PFC) (Figure 2A).  
Some studies report acute Δ9-THC-induced impairment of behavioural inhibition and increases 
in impulsivity, but findings on attention, decision-making and risk-taking tasks are mixed and 
task-dependent25, 27. There is also some evidence that acute effects may vary depending on an 
individual’s previous level of use of the drug. Tolerance to the memory-impairing28 and 
psychomotor effects29 of acute Δ9-THC have been shown in individuals who use the cannabis 
more than once a week, probably reflecting a downregulation of cortical CB1Rs30, 31 (Figure 
2B). 
 
There is some evidence that acute effects of Δ9-THC cannabis on memory depend on the 
particular type of cannabis ingested. Smoking cannabis with higher levels of CBD protected 
regular users against the acute memory-impairing effects of Δ9-THC10. Findings in cannabis-
using volunteers replicated these protective effects of CBD on Δ9-THC-induced acute memory 
impairment11. Indeed, CBD alone has been shown to enhance fear extinction learning in 
humans7. This further supports the notion that CBD and Δ9-THC may have opposing effects 
on some of the neural substrates of human memory32. A recent cross-sectional study found that 
CBD appeared to protect against the effects of Δ9-THC on hippocampal volume loss33. Future 
research should determine whether chronic exposure to CBD might be protective in the longer 
term.  
 
Long-term effects. Although in several countries legislation enables new studies of medical 
cannabis to use prospective, randomized controlled trial designs, to date studies of the 
neurocognitive effects of repeatedly using cannabis (that is, the long-term or chronic effects) 
have relied mainly on retrospective, self-reported drug use by people who choose to use 
cannabis recreationally, and, in most cases, illicitly. More objective indices of drug use can be 
obtained through hair samples, although such analysis has limitations (for example, they are 
influenced by hair dyes)34 and have been rarely used in studies. Long-term impairments in 
memory have been reported mainly in frequent, heavy users, but confounding factors make it 
difficult to establish cause–effect relationships between cannabis use and changes in 
neurocognitive function. Such factors include baseline cognitive function prior to drug use; use 
of other cognitively impairing drugs like alcohol; types of cannabis used; age at which use 
started; and mental health problems, including depression and cannabis addiction. 
 
Case-control studies of non-acute effects of cannabis have produced inconsistent findings to 
date, but tend to mirror acute findings. The most consistently reported long-term effects in 
these studies are impairments of encoding new episodic memories, with some studies finding 
persistent deficits in the first few days of abstinence but little evidence of persisting deficits at 
28 days after use25. Meanwhile, the findings for measures of working memory, attention and 
impulsivity are mixed. One study35 found no difference in decision making or risk taking 
between cannabis users and non-users who were matched for potential mental health 
confounds. However, poorer decision-making accuracy in users was significantly associated 
with the number of symptoms of cannabis addiction.  
Functional neuroimaging studies often reveal subtle differences between chronic cannabis 
users and controls in brain activity during performance of cognitive tasks; again, the persistence 
and clinical importance of these differences remain to be determined. A systematic review36 of 
43 studies concluded that chronic cannabis use may alter brain structure and function in both 
adult and adolescent users (particularly in the medial temporal and frontal cortices, and 
cerebellum). However, the findings of the mainly cross-sectional studies displayed remarkable 
heterogeneity and it was not possible to infer causation. Further, deficits are most consistently 
observed only among heavy users — those most likely to be addicted to cannabis. Cognitive 
changes related to chronic exposure to cannabis or Δ9-THC observed in humans and in animal 
model studies (such as reduced inhibitory control and impaired decision making)27, 37, 38 are 
implicated in the maintenance of addiction39. in part by impairing the reversal of behaviors 
related to drug acquisition/taking that propel continued drug use despite negative 
consequences. It could thus be proposed that these cognitive changes may interact with genetic 
vulnerability factors to increase the risk of developing cannabis addiction.  
Age-dependent effects: adolescence and adulthood. The eCB) system has a major role in 
neurodevelopmental and maturational processes including synaptic pruning and white-matter 
development, and these processes are especially prevalent during adolescence. As exogenous 
cannabinoids affect the functioning of the eCB system, it is plausible that prolonged use 
during adolescence disrupts the neurodevelopmental maturational processes during this 
period40. Thus, the human brain may be more vulnerable to drugs at the time when use of 
cannabis often begins. 
 
Preclinical studies have shown that repeated exposure to Δ9-THC has a greater negative impact 
on the working memory, object recognition, and pre-pulse inhibition of adolescent than on 
adult rodents40. Chronic administration of CB1R agonists or Δ9-THC to adolescent rats 
produces persisting impairments in object recognition memory that are not seen with the same 
treatment in adult rats41, 42, as well as greater alterations in the level of expression of various 
hippocampal proteins (which may account for adolescent-specific memory effects42). A single 
dose of Δ9-THC has also been found to result in greater acute impairments to spatial and non-
spatial learning in adolescent rats than in adult rats43.  
 
The age-related effects of cannabis use on cognitive function may therefore be dependent on 
the maturational state of the neural circuits that are affected by the drug. This may reflect the 
fact that Δ9-THC induces perturbations in the crucial influence of the eCB signalling that is 
involved in brain development, for processes including neural proliferation, morphogenesis, 
neural migration and synaptogenesis44-46. Consistent with this interpretation were the results 
of a study in which Δ9-THC was repeatedly administered over 6 months to adolescent 
monkeys in doses that corresponded well to human self-administration (approximately 1–2 
joints, 5 days per week). This repeated administration blunted the usual pattern of accuracy 
improvements on a test of spatial working memory (which matures after object working 
memory), but not on an object working memory task47. Thus, the persistent effects of Δ9-
THC on cognition in animals are more evident when exposure coincides with the 
developmental stage during which cannabinoid-affected neural circuits are actively maturing.  
 
Similarly, there is also accumulating evidence in humans that neurocognitive function and 
aspects of brain architecture are more disrupted by cannabis when individuals start using it 
during adolescence, although there is a scarcity of direct comparisons with adult users. Some 
structural imaging studies in adolescent and young adult cannabis users have reported 
decreased volume in several cortical and sub-cortical regions36 but findings across different 
studies vary considerably48. For example, although structural differences between adolescent 
cannabis users and controls in orbitofrontal cortex (OFC) volume have been found, smaller 
volumes at 12 years of age were shown to predict cannabis use at 16, suggesting that 
differences in the OFC may be a vulnerability factor for use rather than a consequence49. And 
although smaller hippocampal volumes in cannabis users have been associated with age of 
onset of use, this association appears less consistent does the association between reductions 
in the size of the hippocampus and the amount of use, suggesting that the structure of the 
hippocampus may be more affected by duration and intensity of exposure rather than by early 
use specifically50.  
 
Diffusion tensor imaging (DTI) studies have found poorer white-matter integrity (indexed by 
both lower fractional anisotropy and higher mean diffusivity) in adolescents who use 
cannabis frequently compared with control non-users48. Further, reductions in those indices 
of white-matter integrity correlate with deficits in measures of neurocognitive performance.  
 
Several functional MRI (fMRI) studies suggest that there is increased BOLD signal in task-
related areas in young cannabis users compared with non-using controls48. For example, Jager 
and colleagues51 assessed 13–19-year-old boys who had used cannabis at least 200 times in 
their lives and compared them with non-using, age-matched controls. The cannabis users 
showed greater activation in prefrontal regions during a working memory task than did 
controls. Overall, most functional imaging findings suggest that adolescent cannabis users 
show increased recruitment of neural resources — potentially reflecting compensatory 
activity — in brain areas subserving task-related processing.  
 
In terms of neurocognitive function, individuals who started using cannabis during adolescence 
have been reported to have greater deficits in visuospatial attention52, verbal fluency53 and 
inhibition53 than do those who start in adulthood. Importantly, based on the Dunedin 
prospective cohort data, one study54 concluded that having cannabis addiction that started 
during adolescence and persisted into adulthood was associated with a decline of around 8 IQ 
points (Box 1). However, two recent, large-scale studies cast doubt on a causal explanation 
(Box 1). 
 
One limitation of the studies to date assessing the effects of cannabis use on the adolescent 
brain is that they have focused on age (whereby onset of use before 15–17 years of age is 
considered ‘early’) rather than on adolescent pubertal markers or potential sensitive periods 
that may more accurately index stage of brain development55. Since the eCB system interacts 
with gonadal hormones, and girls typically begin puberty earlier and reach pubertal maturation 
earlier than boys, pubertal stage may influence findings on sex differences. The few studies 
looking at acute effects of cannabis or Δ9-THC have produced little in the way of age-dependent 
sex differences although chronic differences may exist25.  Younger age of regular cannabis use 
onset predicted poorer memory in women but not men56. Surprisingly, the same study found 
earlier age of cannabis use initiation predicted better decision-making performance in both 
male and female cannabis users. Maturation of the PFC and its connections with the limbic 
system occurs earlier in girls57 and this difference may contribute to reported sex differences 
in the effects of adolescent cannabis use25, 56. The paucity of studies of sex differences in the 
effects of cannabis limits conclusions and should be addressed by future research.  
 
Effects persisting after stopping use. Several studies of long-term effects after an individual 
stops using cannabis are converging to show that cognitive impairments do not persist beyond 
4–6 weeks after abstinence58, 59. Using positron emission tomography (PET) imaging, one 
study30 demonstrated that chronic cannabis users showed a downregulation of cortical CB1Rs 
that correlated with years of use. After ~4 weeks of continuously monitored abstinence from 
cannabis at a secure research unit, their CB1R density returned to control levels, further 
supporting recovery within 4 weeks, and even, according one recent study, after as little as 2 
days31. Reversible downregulation of brain CB1Rs after chronic exposure to cannabis has also 
been shown in rodent studies60. Other studies of ‘persisting’ effects have used structural and/or 
functional imaging but with cross-sectional designs, different abstention intervals and a range 
of confounds (including group differences in comorbid alcohol use and pre-cannabis level of 
functioning), which make it difficult to draw any causal conclusions. Longitudinal studies are 
thus needed to determine whether these effects of abstinence are seen even in those starting use 
in adolescence61.  
 
4. Cannabis addiction  
Much research on cannabis and mental health has focused on psychosis (Box 2), although 
addiction is a far more common problem: we estimate that people who try cannabis are 9-fold 
more likely to become addicted to it than to develop psychosis in their lifetime62-64. In this 
section, we introduce the concepts of cannabis addiction and withdrawal, review the rewarding 
effects of cannabinoids in relation to eCB, dopaminergic, opioid and noradrenergic 
neurotransmitter systems, and highlight vulnerability factors and possible treatments for 
cannabis addiction. 
 
Cannabis addiction and withdrawal. The term ‘addiction’ is in a terminological quagmire; 
here, however, we define it as an acquired, chronic, relapsing disorder that is characterized by 
a powerful motivation to continually engage in an activity despite persistent negative 
consequences. Addictive drugs can all cause similar changes to brain circuits underpinning 
reward, salience, impulsivity, compulsivity, learning and memory39, 65-67 although these differ 
according to class of drug (including cannabis)68, 69. Clinical problems associated with cannabis 
use were previously diagnosed as ‘cannabis abuse’ or ‘cannabis dependence’ in the Diagnostic 
and Statistical Manual for Mental Disorders, fourth edition, text revision (DSM-IV-TR). In the 
most recent version (DSM-5) these categories were amalgamated into a single diagnosis of 
‘cannabis use disorder’ (CUD) as described in Box 3. The chances of becoming addicted to 
cannabis after lifetime exposure is 8.9%, which is comparatively lower than for cocaine 
(20.9%), alcohol (22.7%) or tobacco (67.5%)64. Nevertheless, the clinical need for treatment 
of cannabis addiction is substantial and increasing in North America, Europe and Oceania5. 
Across Europe, cannabis now accounts for more first-time entrants to drug treatment services 
than does any other illicit drug70. 
 
A specific cannabis withdrawal syndrome – one aspect of addiction - is well recognized and 
affects around 50% of daily users upon cessation of use, and typically begins 1–2 days after 
cessation, peaks at 2–6 days and remits at 1–2 weeks71. Prominent symptoms include craving, 
sleep problems, nightmares, anger, irritability, dysphoria and nausea72. Cannabis withdrawal 
symptoms correlate with reductions in CB1R availability during acute abstinence31 and can be 
alleviated by Δ9-THC in a dose-dependent manner73. Δ9-THC withdrawal is associated with 
increased release of the stress peptide corticotropin releasing-factor (CRF) in the central 
nucleus of the amygdala74, 75. Similar increases in amygdalar CRF release are evident during 
withdrawal from most classes of recreational drugs (including nicotine, alcohol, 
psychostimulants and opiates), and contribute to negative affective states and decreased brain 
reward function76. It is therefore noteworthy that cannabis is frequently rolled with tobacco in 
‘joints’ and many users also smoke cigarettes (Box 4). In daily users of cannabis and tobacco, 
individual withdrawal effects appear similar for both drugs; combined withdrawal produces 
stronger effects than does withdrawal for either one alone77. 
 
Cannabinoids and reward. Δ9-THC produces the effects cannabis users seek; they report liking 
it and wanting more24. Additionally, cannabis with higher Δ9-THC content (for example, 3.5% 
versus 2.0%) produces stronger reinforcement in human choice paradigms78. Since 
reinforcement of drug use is considered to be one component in the transition from voluntary 
to compulsive use67, these findings suggest that high-THC cannabis might increase 
vulnerability to addiction. However, it is difficult to extrapolate these findings to modern, high-
potency cannabis with ~15% Δ9-THC16-18. Recent naturalistic studies indicate that people adapt 
to rising Δ9-THC concentrations by adding less cannabis to their joints79 and/or inhaling less 
smoke80. Nevertheless, cross-sectional data suggest that use of high-THC forms of cannabis is 
associated with greater addiction severity81. It is therefore possible that recent increases in 
cannabis potency15, 16 might have contributed to the rising demand for treatment of cannabis 
addiction5, 70.  
 
The presence or absence of CBD in evaluations of Δ9-THC reward may also be relevant. One 
study found that people who smoked cannabis containing only low levels of CBD were more 
prone to have their attention captured by cannabis-related stimuli than were those smoking 
high-CBD cannabis82. This suggests that CBD could protect against addiction, as attentional 
bias toward drug-related stimuli correlates with craving and is sensitive to relapse-provoking 
manipulations83. However, CBD does not influence the acute reinforcing effects of cannabis or 
the rewarding feeling of being ‘stoned’82, 84, 85. 
 
The rewarding effects of cannabinoids in animals depend on species, route of administration 
and experimental design. Rats will perform an operant behaviour to receive Δ9-THC infusions 
into the brain ventricular space and to receive CB1R agonist infusions into the nucleus 
accumbens shell and posterior VTA86, 87, as with other drugs of abuse.  However, there has 
been substantial difficulty in establishing operant intravenous Δ9-THC self-administration in 
rodents78, possibly owing to the prolonged pharmacokinetic effects of Δ9-THC that impede 
establishment of discrete response–reward associations. The higher cognitive function in 
primates may allow for clearer discernment as to whether lever pressing behavior is causal for 
the somewhat delayed alterations in reward state resulting from intravenous Δ9-THC. It is also 
possible that the aversive and motor-depressant effects of Δ9-THC present greater impediments 
to self-administration in rodents than in primates.  
 
Consistent with the human literature, studies in rats also demonstrate that Δ9-THC reward is 
dose-dependent. These effects appear to follow an inverted U-shaped curve whereby high Δ9-
THC doses are less reinforcing than medium doses. For example, as indexed using the 
intracranial self-stimulation (ICSS) paradigm, reward system function in the rodent brain is 
enhanced by low doses of Δ9-THC88, whereas higher doses and more-potent CB1R agonists 
can decrease this function89, 90. Consistent with this, the rewarding effects of low doses of Δ9-
THC or CB1R agonists in the conditioned place-preference paradigm are supplanted by 
aversive effects at higher doses86, 91, 92. An inverted-U shaped profile is consistent with data 
from human studies that indicate that high-THC cannabis is preferred and associated with 
greater addiction severity than low-THC cannabis81 whereas extremely potent products (such 
as synthetic CB1R agonists) are less addictive than ‘natural’ cannabis, have more negative 
effects and are only preferred by 7% of users93.  
 
In animals, CB1R antagonism produces a ‘rightward’ shift along this inverse U-shaped reward–
aversion dose-effect function, blocking the rewarding effects of low doses of CB1R agonists 
and preventing the aversive effects of high CB1R agonist doses. This underscores the bimodal 
effects of CB1R activity on brain reward processing. Squirrel monkeys voluntarily self-
administer intravenous Δ9-THC94 and rats reliably self-administer synthetic CB1R agonists95, 
96 — actions that are prevented by CB1R antagonism. Taken together, these studies suggest 
that the CB1R activity has a crucial role in cannabinoid reinforcement and cannabis addiction. 
 
Similar to 9-THC and many synthetic cannabinoid agonists, eCBs exhibit agonist effects at 
brain CB1Rs.  The eCB AEA takes its name from the Sanskrit word ‘ananda’, meaning ‘bliss’. 
Although pharmacologically enhanced eCB signalling (for example, through the inhibition of 
eCB clearance) generally does not produce rewarding effects per se, persistent disruptions in 
eCB signalling appear to contribute to facets of drug dependence across drug classes97, 98. 
CB1R downregulation in chronic cannabis users has been reported in three studies 30, 31, 99; 
these effects subside within days to several weeks of sustained abstinence30 31. Similarly, 
rodents chronically exposed to Δ9-THC or synthetic CB1R agonists exhibit a reduction in 
CB1R function throughout the brain100, 101 that persists for days to weeks following Δ9-THC 
treatment, followed by a functional recovery that varies between brain regions102. eCB-
mediated forms of synaptic plasticity in the nucleus accumbens and hippocampus are abolished 
following exposure to Δ9-THC or CB1R agonists101, 103, 104 — and this may substantially impact 
reward processing and memory processes mediated by these regions. Chronic exposure to Δ9-
THC or CB1R agonists increases enzymatic clearance of AEA and reduces brain tissue AEA 
content in rodents19, 105, 106, and consistent with these data, frequent cannabis smokers exhibit 
decreased AEA levels in CSF107. Although evidence is limited, elevated serum AEA levels 
may be evident in  ex-users of the drug 108.  
 
Dopamine, opioids and noradrenaline. Human PET studies indicate that Δ9-THC can increase 
dopamine release in the striatum109 although to a far lesser extent than do other recreational 
drugs, and not in all studies110. In rodents, Δ9-THC and CB1R agonists increase the firing rate 
and bursting activity of VTA dopamine neurons, resulting in dose-dependent increases in the 
mesocorticolimbic release of dopamine111-113. Conversely, withdrawal from chronic Δ9-THC 
or CB1R agonist exposure is associated with decreased firing of dopaminergic cells and 
decreased dopamine release in the nucleus accumbens114, 115. Consistent with these 
observations in animal models, reduced capacity to synthesize striatal dopamine was recently 
reported in human cannabis users, particularly among addicted individuals116. However, in 
humans, chronic cannabis exposure is not typically associated with abnormalities in striatal 
dopamine release or in D2 receptor expression
117 and, together with the modest dopaminergic 
effects of acute Δ9-THC, the available human data provide only weak support for dopaminergic 
involvement in cannabis addiction.  
 
Δ9-THC-induced increases in opioid peptide release118, 119 may also contribute to the rewarding 
effects of cannabis. The opioid receptor antagonist naltrexone reduces Δ9-THC-induced 
increases in mesolimbic dopamine release, intravenous Δ9-THC self-administration and 
intracerebroventricular CB1R agonist self-administration in rats and monkeys120, 121. Sixteen 
days of naltrexone treatment reduced self-administration and some positive subjective effects 
of Δ9-THC in humans122.  
 
Δ9-THC and other CB1R agonists stimulate noradrenergic cell firing and increase levels of 
noradrenaline in multiple brain regions in which the neurotransmitter can impact motivated 
behaviours123 — including the nucleus accumbens, prefrontal and cerebral cortices, 
hippocampus and hypothalamus124-126. The behavioural importance of CB1R agonist-induced 
increases in noradrenaline release has not been carefully evaluated, although evidence suggests 
it may contribute to the aversive (but not anxiogenic) effects of high doses of CB1R agonists127. 
For example, the aversive effects of high doses of the CB1R agonist WIN 55,212-2 (as 
measured in the conditioned place-aversion paradigm) are reduced by attenuation of 
noradrenergic signalling in the nucleus accumbens, although WIN 55,212-2-induced anxiety-
like behaviour (as measured on the elevated plus-maze) is not reduced by these 
manipulations127. 
 
Vulnerability factors. Irrespective of the drug constituents81, 82, only a minority of cannabis 
users become addicted; therefore, other factors must predict vulnerability. Concurrent tobacco 
use has been identified as a risk factor in a number of studies128-130, as have early adolescent 
onset and frequent (especially daily) use131 128. Males typically have an earlier opportunity to 
use cannabis, a greater risk of addiction and a faster progression from first opportunity of use 
to addiction64, 128, 129. These findings are consistent with normative data from European 
treatment services: the mean age of first treatment is 24, the mean age at first cannabis use is 
16 and 83% of treated individuals are male70.  
 
Interestingly, a 3-year prospective study of daily users found that variables related directly to 
cannabis use did not predict transition to addiction; more important were current factors such 
as living alone, coping motives and negative life events (such as having had a major financial 
crisis)80. A meta-analysis of 24 twin studies132 suggested that genetic influences account for 
55% of the vulnerability to cannabis addiction, with shared environmental factors and non-
shared environmental factors accounting for much lower proportions (17.5% and 27.5%, 
respectively). Although isolated studies have identified specific gene variants associated with 
increased risk of developing cannabis use disorder (reviewed in ref. 133), cannabis addiction 
phenotypes are likely to be polygenic, and genotypes probably overlap with those linked to 
substance addiction in general134.  
 
Possible treatments for cannabis addiction. Cannabis addiction is not easily treated by 
psychological therapies135, and although many pharmacotherapies, have been tested136 — 
including antidepressants, anxiolytics, noradrenaline-reuptake inhibitors, anticonvulsants, 
glutamatergic modulators and CB1R agonists — none has been approved. Based on existing 
clinical trial data, a 12-week trial of the GABA mimetic gabapentin137 and an 8-week trial of 
N-acetylcysteine138 have shown promise for reducing cannabis use according to urine sampling 
during treatment. Gabapentin also improved a number of secondary outcomes, including 
withdrawal symptoms, executive function and self-reported depression137. CB1R agonists such 
as dronabinol (oral synthetic Δ9-THC)139 and nabiximols140 (an oral spray containing Δ9-THC 
and CBD in equal ratio) attenuated cannabis withdrawal symptoms and improved treatment 
retention, but did not reduce cannabis use compared with placebo. These findings suggest that 
substitution treatments can replace Δ9-THC in cannabis but are not sufficient to promote 
abstinence from it. 
 
Few studies have evaluated the contribution of dysregulated eCB signalling to cannabis 
addiction and related physiological and behavioural disruptions. However, eCBs provide 
important homeostatic regulation over emotional state141 and sleep function142, and so it is 
plausible that Δ9-THC-induced impairment of eCB signalling contributes to the negative 
emotional states and sleep disturbances that are present during protracted cannabis 
abstinence71-73. Intriguingly, studies in rodents demonstrate a palliative effect of 2-AG-
clearance inhibitors on the somatic symptoms of CB1R-antagonist-precipitated Δ9-THC 
withdrawal105. Collectively, these observations have led to the proposed use of eCB-clearance 
inhibitors as treatments for cannabis withdrawal, and perhaps addiction143, 144. Given the largely 
unmet clinical need, developing effective pharmacological treatments should be a top research 
priority.  
 
Cannabis, anxiety and depression  
Like most addictions, cannabis addiction is often comorbid with other mental health problems. 
Epidemiological evidence indicates a possible association between regular cannabis use and 
the development of anxiety and depression. However, the evidence is more mixed and less 
consistent than that between cannabis use and psychosis62. One recent study compared the 
mental health of individuals who were addicted to cannabis (according to the DSM-IV) with 
that of non-addicted cannabis users who had similar patterns of cannabis use. Only the addicted 
users had depression and anxiety problems145. Compared with general population norms, non-
addicted frequent users were more likely to show externalizing disorders (such as attention-
deficit hyperactivity disorder) that were likely to have predated their cannabis use. Otherwise, 
these individuals were similar in terms of mental health to the general population, suggesting 
that cannabis contributes to mental health problems only in those who are vulnerable for other 
reasons.  
Depression and anxiety disorders not only are associated with cannabis addiction146 but also 
are predictive of whether individuals transition from use to addiction147. Strikingly, a high 
number of cases of depression and anxiety disorders were reported among obese individuals 
who were treated with the anti-obesity drug Rimonabant, a CB1R antagonist. Many of these 
individuals had no prior history of these disorders148, 149 and this led to the withdrawal of 
Rimonabant from therapeutic use. These findings suggest that CB1R antagonists increase the 
risk of depression and/or anxiety. Moreover, preclinical studies have shown that mice that 
genetically lack CB1Rs show increased depressive-like symptoms150 and, in wild-type mice, 
CBD has antidepressant effects151. Rodent studies have implicated the eCB system in the 
regulation of emotion152. Similarly, there are also data from rodent studies suggesting that 
impaired CB1R signalling leads to depression-like symptoms, and that enhancement of CB1R 
signalling produces antidepressant-like behavioural effects in rodents153. 
 
In our own studies of young (16–24-year-old) daily cannabis users, we have found that levels 
of Δ9-THC in hair are significantly associated with self-reported levels of both depression and 
anxiety154. However, a recent epidemiological study146 suggested that increases in self-reported 
depression in cannabis users are not long-lasting, as no consistent associations were found 
between adolescent cannabis use and depression at age 29. By contrast, the same study showed 
daily cannabis use and cannabis addiction in early adulthood was associated with more than 
double the non-user control rate of anxiety disorders at 29. The association between cannabis 
use and anxiety may arise because the same factors that predispose people to use cannabis also 
predispose them to anxiety. Indeed, there is accumulating evidence that in vulnerable 
individuals, cannabis is often ‘used’ to self-medicate social anxiety155, 156. This is interesting, 
as controlled studies of acute effects in humans have shown that Δ9-THC increases anxiety6, 
whereas CBD decreases it9. Furthermore, Δ9-THC and CBD acutely produce opposite but 
subtle effects on human facial affect recognition84 and amygdala activation when viewing 
fearful faces32. 
 
The interconnectedness of cannabis use, mental health problems and cognitive functioning is 
important. It is inherently difficult to determine causality in the type of studies discussed above 
because factors besides cannabis use (e.g. premorbid cognitive and emotional function) may 
be directly associated with risk of mental illness. Such factors could predispose an individual 
both to mental illness and to using cannabis3, and the combination of these disorders would in 
turn increase their impact upon cognitive functioning.  
 
5. Conclusions and future directions 
Cannabis has been used for thousands of years for a range of medicinal properties as well as 
for its desired psychological and social effects, which recreational users value. This use can, 
however, carry a penalty: a range of undesired effects that vary in the severity of their impact 
on the individual’s life. Although evidence of clear causality is lacking, these undesired effects 
may range from mild cognitive impairment to disabling psychiatric disorders. However, most 
recreational and medical users appear to rate the benefits as outweighing the risks in choosing 
to continue their cannabis use. It should be noted that public health messages to users are 
distorted, because funding for research is often targeted to studying the harmful effects of 
cannabis and ignores benefits. Despite studies aiming to document negative effects, 
occasionally positive effects are noted such as enhanced divergent thinking following either 
oral THC or smoked cannabis24, 157. Future research should evaluate perceived benefits to give 
a more balanced understanding; people clearly do not use cannabis only for its harms.  
 
Throughout this article we have specified gaps in our knowledge. Although problems 
associated with cannabis use are mainly observed in heavy, frequent users, we are still not sure 
what level of use of what type of cannabis is non-problematic. We need such data for harm-
reduction advice for both medical and recreational users.  
 
Another question that needs answering is: how does repeated use of cannabis causally affect 
the human adolescent and adult brain given that most cannabis users also use alcohol, another 
cognitively impairing drug? A recent comparison of daily cannabis users who also drank 
alcohol and alcohol-intake-matched, non-using controls in both adolescents and adults found 
no differences in brain structure between the two groups158, but longitudinal data are currently 
lacking. It is also still unclear exactly how the effects of cannabis vary across clinical 
populations. For example, a meta-analysis of showed that people who are diagnosed with 
schizophrenia and use cannabis function better cognitively than individuals with schizophrenia 
who do not use cannabis159. Finally, we need to understand more about how variants of the 
drug produce differential effects — variants not only in constituent cannabinoids but also the 
new synthetic cannabis variants (such as ‘spice’)93 as well as new forms of administration (for 
example, through vaping or edible forms)160.  
 
Future studies will help to fill these gaps of knowledge, especially if they incorporate 
methodological improvements. Most studies of long-term effects assess level of cannabis use 
through various self-report measures (such as frequency, years of use, time to smoke a specific 
amount of the drug) and could benefit from improved biomarkers such as Δ9-THC and CBD 
levels in hair. We need longitudinal studies that follow young people from before puberty (that 
is, prior to drug use), through biologically defined puberty and into adulthood (while 
monitoring drug use) and again after subsequent abstinence or not. Such studies would use a 
comprehensive range of assessments (including: tests of cognition, motivation, brain function 
and mental health; biomarkers of different types; and quantities of cannabis or cannabinoids 
and other recreational substances used) so the interactions among these factors may be 
monitored. This need should be addressed by the US National Institutes of Health-funded 
Adolescent Brain Cognition Development (ABCD) Study: a prospective, 10-year, longitudinal 
study of 10,000 individuals beginning at 9–10 years of age. This study is designed to assess the 
impact of substance use on brain development and neurocognitive function through a battery 
of measures obtained prior to cannabis use, following use at various levels and again following 
cessation of use. Given recent changes in the medical and legal status of cannabis in some 
countries, randomized controlled trials of the effects of different types and doses of cannabis 
can now be conducted. Work with animals will be important in delineating chronic effects, and 
studies administering doses and schedules within a human-relevant range (as exemplified in 
Ref. 47) are the most helpful.  
 
The number of cannabis addicts may well grow as cannabis use becomes more acceptable and 
the drug more accessible. Indeed, there is evidence that this is already happening in the United 
States161. It is therefore urgent that we increase efforts to understand what factors influence the 
development of addiction and build preventative efforts against this. Currently, we lack an 
effective pharmacological treatment for cannabis addiction that can be used conjointly with 
psychosocial therapies to boost the current low efficacy of all treatment approaches. This need 
requires urgent research attention. 
 
With hindsight, we can clearly see the enormous problems that have been caused to many 
individuals and to society by tobacco and alcohol. Unlike cannabis, these drugs are legal in 
most countries, despite the fact that, if asked to decide today which psychoactive drugs should 
be legal, cannabis (which rarely kills people) might well be judged as being comparatively 
benign. Legislative changes would help researchers, as current restrictive drug scheduling 
markedly hinders neuroscience research and the innovation of psychiatric treatment162. More 
importantly, if handled carefully from a harm-reduction standpoint, a regulated market might 
increase the control over the age of initiation of use and other vulnerability factors; inform 
accurately about dosage; and increase the availability of more-balanced cannabis (that is, with 
lower levels of Δ9-THC and higher levels of CBD) to maintain desired effects while reducing 
the incidence of harms.  
__________________________________________________________________________________________ 
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Box 1. Does cannabis affect IQ or educational attainment? 
Case-control and prospective cohort studies have found associations between cannabis use and 
both lower IQ and lower educational attainment. But do these associations reflect any causal 
relationships?  
 
Does cannabis affect IQ? 
To date, there have been three large prospective cohort studies that have assessed the 
relationship between cannabis use and IQ.  
In a New Zealand birth cohort study of 1,037 38-year-olds born in 1972 or 1973, persistent 
cannabis dependence was associated with a decline of up to 6 IQ points from that measured at 
age 7-13 years54. The decline was particularly evident for those who developed cannabis 
dependence in adolescence, and remained apparent even for those who, at age 38 years, used 
cannabis less than once a week.  
By contrast, a UK birth cohort study of 2,235 15–16-year-old adolescents born in 1991 or 1992 
found that cumulative cannabis use was not associated with a lower IQ compared with non-
using controls, once IQ measured pre-teen and various potential confounders (in particular, the 
adolescents’ use of cigarettes and alcohol) were accounted for163. Cannabis use was relatively 
low in this study, with only 72 adolescents reporting more than 50 lifetime cannabis exposures.  
A US prospective cohort study of 3,066 17–20-year-olds found no difference in IQ change 
from that measured at age 9-12 years  between monozygotic and dizygotic twins discordant for 
cannabis use164. However, there were only 47 discordant twin pairs in which the cannabis-using 
twin had used cannabis frequently (more than 30 cumulative uses, and/or daily use), limiting 
the strength of any conclusions from this study. 
The UK and US studies therefore both suggest that genetic or environmental factors drive the 
observed associations between lower IQ and cannabis use, although both cohorts included 
younger participants with fewer cannabis exposures than did the New Zealand study.  
To date, all studies have relied on retrospective self-report of cannabis use, have ignored 
possible residual effects of the drug on IQ test performance and have not addressed the potency 
or variety of cannabis used (see main article). Addressing these issues with confirmation of 
exposure to Δ9-THC and other cannabinoids (such as CBD) using hair samples from 
participants may lead to more reliable and consistent findings165. 
Does cannabis use affect educational attainment? 
Several case-control and longitudinal studies have provided fairly consistent evidence of 
associations between adolescent cannabis use and both early school leaving and poorer 
educational performance166-169. But the mechanisms producing these relationships remain hotly 
debated170.  
Causal explanations have posited that heavy cannabis use results in cognitive and/or 
motivational deficits, which in turn result in poorer educational attainment. Although there are 
many anecdotes about an ‘amotivational syndrome’ resulting from heavy cannabis use, a recent 
positron emission tomography study demonstrated that cannabis users had reductions in striatal 
dopamine synthesis that correlated with a measure of amotivation171.  
Alternatively, reverse causality has been also suggested; that is, perhaps poorer educational 
attainment leads to cannabis use166, 168. However, the one study that addressed this hypothesis 
showed that the association between early school leaving and later cannabis use could be 
accounted for by cannabis use before leaving school early166.  
The other alternative is that educational attainment and cannabis use may not be causally 
related but instead share common risk factors168, 170, 172. Reported associations between 
cannabis use and lower educational attainment have typically been robust to adjustment for 
some potential confounders such as early-life factors, baseline school performance or cognitive 
ability, social disadvantage and parental educational achievement) 167, 169. However, the 
potential role of teenage behaviours that typically occur alongside cannabis use — including 
use of other substances and other ‘risky’ behaviours such as truancy — remain relatively 
unexplored163, 170.  
Recent analyses showed that adjusting for teenage use of other substances attenuated the 
association between cannabis use and school attainment163, 173, 174. As such, the existence of 
unmeasured confounds is often posited to account for the negative associations with cannabis 
163, 168, 170. Indeed, this idea is strongly supported by recent genetic studies that found no 
difference in early school leaving170  or years of education175 between both monozygotic and 
dizygotic twin pairs who were discordant for cannabis use170, 175. 
 
Box 2 | Cannabis and psychosis: cause, consequence or correlation? 
Nearly 2,000 studies have been published on this topic since 1962, and the pro-psychotic 
effects of cannabis have dominated media reporting about this drug. But how clear is the link? 
A number of longitudinal, population-based studies show an earlier first episode176 and a 
roughly two-fold increase in risk of psychosis with regular cannabis use62. Yet the vast majority 
of people who use cannabis do not develop psychotic disorders such as schizophrenia, and 
many people diagnosed with such disorders have never used cannabis.  
More agreement is found in evidence that heavy cannabis use may mean that young people 
who are vulnerable to psychosis develop the disorder when they may not have otherwise done 
so. Converging data suggest that this may have a genetic basis, with certain polymorphisms of 
the gene encoding AKT1 potentially conferring risk of psychosis following smoking cannabis 
acutely177 and chronically178, 179.  
The type of cannabis used has recently been found to impact on risk of psychosis: self-reported 
hash use, even daily, is not associated with increased risk of psychosis, whereas self-reported 
daily use of skunk (which contains high levels of Δ9-THC and negligible amounts of CBD) is 
associated with a five-fold greater chance of having schizophrenia180. Several studies using 
objective biological markers of use have shown that CBD reduces the psychosis-like effects of 
THC154, 181  
How cannabis interacts with the brain to increase psychosis risk is unclear. One confusing 
finding is that of reduced dopamine release in cannabis users116, which seems inconsistent with 
the higher levels of dopamine release observed in people with psychosis. Disruptions in the 
brain’s endocannabinoid system, on the other hand, have been found in psychosis and may 
provide clues as to the pro-psychotic impact of cannabis. Higher levels of anandamide (AEA) 
in the cerebrospinal fluid have been associated with lower psychotic symptoms in individuals 
diagnosed with schizophrenia182, in individuals classified as having prodromal schizophrenia183 
who do not smoke cannabis and in cannabis users without a diagnosis of schizophrenia107. AEA 
is known to have a neuromodulatory role in the brain; thus, during prodromal or first-episode 
psychosis, AEA may be increased to attempt to control dysregulated brain dopamine184.  
In addition, in vivo positron emission tomography imaging and postmortem receptor 
autoradiography studies have consistently reported higher levels of ligand binding to 
cannabinoid 1 receptors in several cortical regions of people with schizophrenia185. Whether 
these alterations are part of the disease pathology or a compensatory response remains unclear, 
but they do suggest a molecular basis for a heightened sensitivity to cannabis of individuals 
with schizophrenia, and perhaps of those at risk. 
 
 
Box 3: ‘Cannabis use disorder’  
Cannabis related problems vary on a continuum and it is important to define these not only for 
clinical diagnosis and treatment but also for research.  The Diagnostic Statistical Manual 
Edition, fifth edition (DSM-5)186 has combined the definitions for ‘cannabis abuse’ and 
‘cannabis dependence’ to provide criteria for the diagnosis of ‘cannabis use disorder’ (CUD). 
DSM-5 states that CUD is: “A problematic pattern of cannabis use leading to clinically 
significant impairment or distress, as manifested by at least 2 of the [symptoms from the three 
lists below], occurring within a 12-month period186”. Mild CUD is associated with having 2 or 
3 of these symptoms, moderate CUD, with 4 or 5 symptoms, and severe CUD, with 6 or more 
symptoms.  
One advantage of combining abuse and dependence criteria in CUD is to provide a clearer 
continuum between mild and severe, because previously all cases of dependence also met 
criteria for abuse. Another advantage is that dependence is often a normal bodily response to a 
substance (for example, a prescribed pain killer) which should not to be confused with 
addiction (insomuch as stopping use of that pain killer does not necessarily lead to drug-
seeking).  
  
The following symptoms were included from DSM-IV criteria for cannabis dependence: 
 Cannabis is often taken in larger amounts or over a longer period than was intended 
 There is a persistent desire or unsuccessful efforts to cut down or control cannabis use 
 A great deal of time is spent in activities necessary to obtain cannabis, use cannabis, or 
recover from its effects 
 Important social, occupational, or recreational activities are given up or reduced 
because of cannabis use 
 Cannabis use is continued despite knowledge of having a persistent or recurrent 
physical or psychological problem that is likely to have been caused or exacerbated by 
cannabis 
 Tolerance, as defined by either [1] a need for markedly increased cannabis to achieve 
intoxication or desired effect or [2] a markedly diminished effect with continued use of 
the same amount of the substance 
 Withdrawal, as manifested by either [1] the characteristic withdrawal syndrome for 
cannabis or [2] cannabis is taken to relieve or avoid withdrawal symptoms 
The following symptoms were included from DSM-IV criteria for cannabis abuse:  
 Recurrent cannabis use resulting in a failure to fulfil major role obligations at work, 
school, or home 
 Continued cannabis use despite having persistent or recurrent social or interpersonal 
problems caused or exacerbated by the effects of cannabis 
 Recurrent cannabis use in situations in which it is physically hazardous 
This item was added as a new symptom to DSM-5: 
 Craving, or a strong desire or urge to use cannabis 
One DSM-IV criterion — concerning persistent legal problems related to cannabis use — was 
dropped and not included in DSM-5 because it largely reflected sociocultural factors to do with 
policing and law enforcement rather than cannabis use factors.   
 
 Box 4: The gateway theory 
Although cannabis is traditionally considered as a ‘soft’ drug, it is widely believed to act as a 
‘gateway’ to harder drugs such as cocaine or heroin (with harm defined in terms of detrimental 
effects of using that substance on the individual and on society). According to this theory, there 
is a sequential progression from one drug to the next (for example, cannabis leading to cocaine, 
and then heroin)187. This theory rests on evidence that use of one drug increases the likelihood 
of using the next drug in the ‘sequence’, which may be interpreted as causal if all other 
confounds are accounted for187.  
Evidence does support sequence and association between cannabis and other illicit drugs, and 
these effects increase with frequency of cannabis use and adolescent onset188. Additionally, a 
twin study189 suggested that these effects cannot be attributed to shared genetic or 
environmental factors alone. Studies in rats demonstrate that adolescent Δ9-THC exposure 
results in increased opiate consumption and facilitated learning of cocaine self-administration 
in adulthood190-192, and that the influence of adolescent Δ9-THC exposure on opiate reward may 
be transgenerational193. 
Establishing causality remains challenging, however, and putative mechanisms remain 
speculative. For example, one possibility is that the wide availability of cannabis means people 
are more likely to use it first and this increases the chances that other illicit drugs are used 
because of contact with other drug users and with people selling illicit drugs189. This formed 
part of The Netherlands’ rationale for the regulated sale of cannabis; incidentally, the rates of 
cocaine use among people who have used cannabis are lower there (22%) than in the United 
States (33%)194.  
Biological explanations for the gateway hypothesis are supported by evidence that exposure to 
THC enhances the reinforcing effects of other drugs. Intriguingly, however, prior Δ9-THC 
ingestion increases rats’ self-administration of nicotine and the reinforcing effects of 
nicotine195, but this does not occur with prior cocaine or heroin exposure196, 197. Indeed, one of 
the most potentially harmful and underappreciated effects of cannabis is the ‘reverse gateway’: 
by smoking tobacco together with cannabis in ‘joints’, individuals may progress to nicotine 
addiction160, 198. 
 
Figure 1 | Cannabinoid 1 receptor distribution within reward-, habit- and cognition-
related circuits. A simplified conceptualization of the major circuits implicated in reward 
(namely, the ventral tegmental area (VTA), nucleus accumbens 211 and ventral pallidum 
(VP))65, 66, 199, stimulus–response habit formation (the dorsolateral striatum (dlStr) and globus 
pallidus (GP))67 and cognition (the prefrontal cortex (PFC), hippocampus (HIPP), and 
amygdalar regions). Among these regions, CB1Rs are expressed with the following order of 
density 200-204: HIPP ≈ basolateral amygdala (BLA) ≈ PFC > VP ≈ GP) ≈ DSTr > NAc > VTA 
≈ bed nucleus of the stria terminalis (BNST) > central nucleus of the amygdala (CeA). Within 
the amygdala, CB1R expression is highest in the lateral and basolateral nuclei, with 
substantially lower expression in the central nucleus 203. In the dorsal striatum there is a 
comparable medial–lateral gradient of CB1R expression with greater levels of expression 
evident in lateral aspects, and comparatively lesser CB1R expression is observed in the NAc204. 
The dense CB1R expression in HIPP, PFC and amygdalar regions underlies the effects of 
cannabis and CB1R agonists on cognitive and memory function, whereas the CB1R presence 
within the mesocorticolimbic regions (VTA, NAc, PFC) contribute to the rewarding effects 
produced by cannabinoids.  
 
Figure 2 | Effects of acute or chronic exposure to cannabis on reward- and cognition-
related circuits. Graphical summary of alterations in neurobiological function resulting from 
chronic cannabinoid agonist exposure based on studies in rodents, non-human primates and 
humans.  These collected observations should be viewed as a model of chronic cannabis 
exposure, rather than an explicit representation of cannabis-induced alterations in human brain 
function. a | Acute cannabis or moderate-dose CB1R agonist exposure induces neurochemical 
events in the mesolimbic system similar to those produced by other drugs of abuse, including 
increased dopamine (DA) release and an attenuation of evoked GABA and glutamate (Glu) 
release in the nucleus accumbens 109, 111-113, 205, 206. The induced increase in opioid peptide 
release in the NAc118, 119 probably also contributes to the acute rewarding effects of Δ9-THC. 
Disruptions in cognitive function (including attention and memory impairments) probably 
result from: decreased acetylcholine (ACh) release in hippocampus (HIPP) and prefrontal 
cortex (PFC)207, 208; reduced GABA release and increased Glu release in the PFC209; and 
increased noradrenaline (NA) release in HIPP and frontal cortical areas124-126. b | Chronic Δ9-
THC or CB1R agonist exposure results in decreased CB1R expression and function in many 
brain regions. Positron emission tomography imaging of daily cannabis users has revealed 
considerable decreases in CB1R levels, particularly in cortical regions30, 31, that correlate with 
years of cannabis use and withdrawal, and rapidly normalise during abstinence30, 31. Rodent 
studies demonstrate regional differences in the effects of chronic Δ9-THC on CB1R expression 
and function, with rapid and profound decreases evident in the hippocampus and layer VI of 
frontal cortex, smaller but still statistically significant decreases in striatal and amygdalar 
regions, and nonsignificant disruptions in regions such as the globus pallidus (GP) and 
hypothalamic nuclei100, 101. The pronounced deficits in cortical and hippocampal CB1R 
function are consistent with memory and cognitive impairments associated with chronic 
cannabis use in humans. In this regard, chronic adolescent Δ9-THC exposure results in 
persistent disruptions of the hippocampal and cortical signalling that is critical for proper 
memory and cognitive functions. Chronic Δ9-THC exposure also disrupts reward-related 
signalling mechanisms in the mesolimbic system by reducing DA cell density in the ventral 
tegmental area (VTA)210 and by decreasing VTA DA cell firing and DA release in the NAc 
during both spontaneous and CB1R antagonist-precipitated withdrawal114, 115. Consistent with 
these observations in animal models, reduced striatal DA synthesis has been observed in human 
cannabis users, and this effect appears to be driven by individuals meeting cannabis use 
disorder criteria116. Together with increased stress-related signalling, such as dynorphin release 
in the NAc211 and corticotropin releasing factor release in the amygdala74, 75, these deficits in 
mesostriatal DA function may contribute to negative affective states associated with THC 
abstinence. Adolescent Δ9-THC exposure also results in persistent increases in opioid peptide 
gene expression and influences the mesolimbic system of rats191, 212, 213, possibly contributing 
to an increase in the rewarding effects of opiates and increase opiate by these animals in 
adulthood190-192, 212. 
 
GLOSSARY  
Cannabis abuse  
Cannabis use that is problematic for various aspects of an individual’s life, (for example, 
causing occupational, educational, or social problems), or that is carried out in dangerous 
contexts.   
 
Cannabis dependence  
A group of severe consequences of repeated cannabis use, including tolerance to effects, 
withdrawal symptoms upon cessation, dysregulation of use, increased involvement with 
cannabis at the expense of other activities, and continued use despite the problems it causes.  
 
Conditioned place-preference (CPP) procedure 
Pavlovian conditioning procedure used to index the motivational properties of drug 
experience. Typically, the different in time spent in an environment associated with drug 
intoxication is compared with that spent in a neutral context.  
 Episodic memory 
Personal, contextualised autobiographical memory of past experiences.   
Intracranial self-stimulation (ICSS) 
An operant paradigm in which animals perform a behavioural response to receive brief 
electrical pulses into specific regions in the brain reward pathways.  
 
Working memory 
The capacity to hold information ‘online’ (maintenance) and manipulate it.  
Long-term depression 
(LTD). An enduring decrease in the strength of neurotransmission at a synapse, implicated 
learning and memory. 
 
Long-term potentiation  
(LTP). An lasting increase in the strength of neurotransmission at a synapse, implicated in 
learning and memory. 
 
Psychosis 
A mental disturbance characterized by aberrant perceptions (hallucinations) and thoughts 
(delusions) that causes an individual to lose touch with external reality. 
 
Reinforcement  
A learning process through which particular stimuli or events (such as familiar drug-taking 
environments, or pleasant drug effects) influence the likelihood or strength of behaviour, such 
as drug seeking. 
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Key Points: 
 Cannabis contain over 100 unique ingredients we call ‘cannabinoids’, and the 
proportions of these vary widely across different strains of the plant. High-delta-9-
tetrahydrocannabinol (9-THC) varieties with negligible levels of cannabidiol (CBD) 
now dominate many Western markets and are more harmful than lower-9-THC, 
higher-CBD varieties. 
 Like other recreational drugs,9-THC increases release of dopamine and opioid 
peptides (in preclinical studies) and alters endocannabinoid processing in the 
mesocorticolimbic reward system. Long-term 9-THC exposure leads to a 
downregulation of brain cannabinoid receptor function that reverses following 
abstinence.  
 People who try cannabis are nine-fold more likely to become addicted to it than to 
develop psychosis. Cannabis addiction is an increasing problem globally and no 
effective pharmacological treatments currently exist — this remains a major unmet 
clinical need.  
 The association between cannabis use and psychosis can be influenced by a number 
of vulnerability factors, including genetics, environmental factors and the frequency 
and type of cannabis used. Evidence linking cannabis use with the development of 
depression and anxiety is less consistent, although these disorders are often comorbid 
with cannabis addiction. 
 The acute effects of cannabis upon cognitive function are well documented and the 
most robust, dose-related decrements are to working and episodic memory.  Its long-
term cognitive effects remain controversial, are influenced by many confounds and 
appear to subside a month after stopping use of the drug. 
 We should ensure that global legislative changes are informed by neuroscience and 
public health. They should mitigate against adolescent uptake and the availability of 
highly potent products, including synthetic agents such as ‘spice’, that act as full 
cannabinoid receptor agonists.  
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